Purpose: The pharmacology, pharmacokinetics, clinical efficacy, safety, drug interactions, dosage and administration, and place in therapy of atomoxetine in the treatment of attention-deficit ...

Dosing of children and adolescents up to 70 kg body weight Initial: The recommended dose is 0.5 mg/kg and increased after a minimum of 3 days to a target total daily dose of approximately 1.2 mg ...

Strattera (atomoxetine) is an oral medication that healthcare providers may prescribe for attention deficit hyperactivity disorder (ADHD). This behavioral disorder can cause hyperactivity ...

Stimulants and atomoxetine are the only effective interventions to reduce short-term adult ADHD symptoms, yet show limited ...

They used data from the IQVIA PharMetrics Plus database. Patients newly prescribed methylphenidate, amphetamines, or atomoxetine during 2010-20 were included. Regular ADHD medicine users had ≥ ...

Stimulants and atomoxetine had short-term benefits in adults with ADHD, but long-term efficacy remains under-investigated. Atomoxetine was less tolerable than placebo. In a large network meta ...

Additionally, the data suggested a decreased PR interval with amphetamines, atomoxetine, and viloxazine; and a decreased QRS complex with methylphenidate. The authors maintained that their work ...

Stimulants and atomoxetine emerge as most effective for core symptoms, but non-pharmacological therapies show promise in specific contexts and long-term data remains limited Study: Comparative ...

Clinical trial data indicate that atomoxetine is safe and well tolerated for the treatment of ADHD; however, safety data about long-term use (greater than one year) are unavailable. Adverse events ...